Entries by Thomas Gabrielczyk

Researchers describe alternative psoriasis target

British researchers have identified interleukin 36 (IL-36) as a druggable proinflammatory driver of psoriasis. Because of its very targeted effects of antibodies directed against the cytokine they want to start clinical tests in man. 

NuCana raises US$114m in IPO of ADSs

Scotch cancer corp NuCana plc was up 3% (to US$18.61) after closing an initial public offering on Friday led by Citigroup, Jefferies and Cowen and co-managed by William Blair.

Researchers unravel patterns of cancer heterogeneity

Up to recently, it was not possible for academic researchers to visualise the spatial distribution of intratumoural heterogeneity within solid tumours. An international research team has now reported a way to track changes with whole-tissue biospy phenotyping.